30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Xtant Medical Reports 3Q16 Revenue -

Xtant Medical (XTNT) posted 3Q16 revenue of US $23.1MM, +10.5% vs. 3Q15, as reported.

ORTHOWORLD estimates 3Q16 segment revenue and as-reported growth as follows.

  • Spine $12.3MM, +9.4%
  • Orthobiologics $10.8MM, +11.8% 


  • Sequentially, 3Q16 revenue increased +7.6% from 2Q16
  • Supply chain issues that lingered in 1H16 are now permanently resolved
  • Revenue from newer products contributed ~$0.6MM to 3Q, comprising 2.5% of revenue overall
  • Remains at 350+ field sales asset headcount and plans to stay at this number through 1H17
  • Portfolio product revenue (a combination of Bacterin and X-spine products) at 7.4% of sales (goal is 10%)
  • First implant of Xspan laminoplasty completed in 4Q
  • New CPT Code 27279 brings reimbursement for Silex product family for treatment of sacroiliac joint disorders

Sources: Xtant Medical, Inc.; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.